SEARCH

SEARCH BY CITATION

References

  • 1
    Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ & Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55, 1030.
  • 2
    Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C et al. (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21, 26832710.
  • 3
    Louis DN, Ohgaki H & Wiestler OD (2007) The 2007 WHO Classification of Tumors of the Central Nervous System. IARC Press, Lyon.
  • 4
    Meyer MA (2008) Malignant gliomas in adults. N Engl J Med 359, 1850.
  • 5
    Behin A, Hoang-Xuan K, Carpentier AF & Delattre JY (2003) Primary brain tumours in adults. Lancet 361, 323331.
  • 6
    Birlik B, Canda S & Ozer E (2006) Tumour vascularity is of prognostic significance in adult, but not paediatric, astrocytomas. Neuropathol Appl Neurobiol 32, 532538.
  • 7
    Leon SP, Folkerth RD & Black PM (1996) Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77, 362372.
  • 8
    Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9, 653660.
  • 9
    Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 11821186.
  • 10
    Folkman J (1972) Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175, 409416.
  • 11
    Folkman J, Szabo S, Stovroff M, McNeil P, Li W & Shing Y (1991) Duodenal ulcer Discovery of a new mechanism and development of angiogenic therapy that accelerates healing. Ann Surg 214, 414425; discussion 426–417.
  • 12
    Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK et al. (1998) Tumor induction of VEGF promoter activity in stromal cells. Cell 94, 715725.
  • 13
    Tandle A, Blazer DG III & Libutti SK (2004) Antiangiogenic gene therapy of cancer: recent developments. J Transl Med 2, 22.
  • 14
    Dameron KM, Volpert OV, Tainsky MA & Bouck N (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin. Science 265, 15821584.
  • 15
    Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA & Bouck NP (1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87, 66246628.
  • 16
    Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, Harper J, Tamvakopoulos G & Moses MA (2000) Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci USA 97, 38843889.
  • 17
    Fidler IJ & Ellis LM (2004) Neoplastic angiogenesis – not all blood vessels are created equal. N Engl J Med 351, 215216.
  • 18
    Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW & Ratcliffe PJ (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94, 81048109.
  • 19
    Shweiki D, Itin A, Soffer D & Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843845.
  • 20
    Vredenburgh JJ, Desjardins A, Herndon JE II, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M et al. (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13, 12531259.
  • 21
    Plate KH, Breier G, Weich HA & Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359, 845848.
  • 22
    Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, Kuwano M & Fukui M (1995) Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 55, 11891193.
  • 23
    Auguste P, Gursel DB, Lemiere S, Reimers D, Cuevas P, Carceller F, Di Santo JP & Bikfalvi A (2001) Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms. Cancer Res 61, 17171726.
  • 24
    Hallbook F, Wilson K, Thorndyke M & Olinski RP (2006) Formation and evolution of the chordate neurotrophin and Trk receptor genes. Brain Behav Evol 68, 133144.
  • 25
    Huang EJ & Reichardt LF (2003) Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 72, 609642.
  • 26
    Nico B, Mangieri D, Benagiano V, Crivellato E & Ribatti D (2008) Nerve growth factor as an angiogenic factor. Microvasc Res 75, 135141.
  • 27
    Kraemer R & Hempstead BL (2003) Neurotrophins: novel mediators of angiogenesis. Front Biosci 8, s1181s1186.
  • 28
    Cantarella G, Lempereur L, Presta M, Ribatti D, Lombardo G, Lazarovici P, Zappala G, Pafumi C & Bernardini R (2002) Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J 16, 13071309.
  • 29
    Donovan MJ, Lin MI, Wiegn P, Ringstedt T, Kraemer R, Hahn R, Wang S, Ibanez CF, Rafii S & Hempstead BL (2000) Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development 127, 45314540.
  • 30
    Nakamura K, Martin KC, Jackson JK, Beppu K, Woo CW & Thiele CJ (2006) Brain-derived neurotrophic factor activation of TrkB induces vascular endothelial growth factor expression via hypoxia-inducible factor-1alpha in neuroblastoma cells. Cancer Res 66, 42494255.
  • 31
    Salmaggi A, Eoli M, Frigerio S, Silvani A, Gelati M, Corsini E, Broggi G & Boiardi A (2003) Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 62, 297303.
  • 32
    Schmidt NO, Westphal M, Hagel C, Ergun S, Stavrou D, Rosen EM & Lamszus K (1999) Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 84, 1018.
  • 33
    Li M & Ransohoff RM (2008) The roles of chemokine CXCL12 in embryonic and brain tumor angiogenesis. Semin Cancer Biol 19, 111115.
  • 34
    Hood JD & Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2, 91100.
  • 35
    Tso CL, Freije WA, Day A, Chen Z, Merriman B, Perlina A, Lee Y, Dia EQ, Yoshimoto K, Mischel PS et al. (2006) Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res 66, 159167.
  • 36
    Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S, Passaniti A, Menon J, Walling J, Bailey R et al. (2006) Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 9, 287300.
  • 37
    Koch U & Radtke F (2007) Notch and cancer: a double-edged sword. Cell Mol Life Sci 64, 27462762.
  • 38
    Diez H, Fischer A, Winkler A, Hu CJ, Hatzopoulos AK, Breier G & Gessler M (2007) Hypoxia-mediated activation of Dll4-Notch-Hey2 signaling in endothelial progenitor cells and adoption of arterial cell fate. Exp Cell Res 313, 19.
  • 39
    Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N et al. (2007) Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445, 776780.
  • 40
    Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I et al. (2006) Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444, 10831087.
  • 41
    Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD & Thurston G (2006) Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444, 10321037.
  • 42
    Boulton ME, Cai J & Grant MB (2008) Gamma-secretase: a multifaceted regulator of angiogenesis. J Cell Mol Med 12, 781795.
  • 43
    Selkoe D & Kopan R (2003) Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci 26, 565597.
  • 44
    Takeshita K, Satoh M, Ii M, Silver M, Limbourg FP, Mukai Y, Rikitake Y, Radtke F, Gridley T, Losordo DW et al. (2007) Critical role of endothelial Notch1 signaling in postnatal angiogenesis. Circ Res 100, 7078.
  • 45
    Ni CY, Murphy MP, Golde TE & Carpenter G (2001) Gamma-secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294, 21792181.
  • 46
    Russell KS, Stern DF, Polverini PJ & Bender JR (1999) Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am J Physiol 277, H2205H2211.
  • 47
    Boulton ME, Cai J, Grant MB & Zhang Y (2008) Gamma-secretase regulates VEGFR-1 signalling in vascular endothelium and RPE. Adv Exp Med Biol 613, 313319.
  • 48
    Hirano H, Lopes MB, Laws ER Jr, Asakura T, Goto M, Carpenter JE, Karns LR & VandenBerg SR (1999) Insulin-like growth factor-1 content and pattern of expression correlates with histopathologic grade in diffusely infiltrating astrocytomas. Neuro Oncol 1, 109119.
  • 49
    Olsson AK, Dimberg A, Kreuger J & Claesson-Welsh L (2006) VEGF receptor signalling – in control of vascular function. Nat Rev Mol Cell Biol 7, 359371.
  • 50
    Jones MK, Itani RM, Wang H, Tomikawa M, Sarfeh IJ, Szabo S & Tarnawski AS (1999) Activation of VEGF and Ras genes in gastric mucosa during angiogenic response to ethanol injury. Am J Physiol 276, G1345G1355.
  • 51
    Takahashi T, Ueno H & Shibuya M (1999) VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18, 22212230.
  • 52
    Takahashi T & Shibuya M (1997) The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 14, 20792089.
  • 53
    Lal BK, Varma S, Pappas PJ, Hobson RW II & Duran WN (2001) VEGF increases permeability of the endothelial cell monolayer by activation of PKB/akt, endothelial nitric-oxide synthase, and MAP kinase pathways. Microvasc Res 62, 252262.
  • 54
    Li B, Xu W, Luo C, Gozal D & Liu R (2003) VEGF-induced activation of the PI3-K/Akt pathway reduces mutant SOD1-mediated motor neuron cell death. Brain Res Mol Brain Res 111, 155164.
  • 55
    Six I, Kureishi Y, Luo Z & Walsh K (2002) Akt signaling mediates VEGF/VPF vascular permeability in vivo. FEBS Lett 532, 6769.
  • 56
    Takahashi M, Matsui A, Inao M, Mochida S & Fujiwara K (2003) ERK/MAPK-dependent PI3K/Akt phosphorylation through VEGFR-1 after VEGF stimulation in activated hepatic stellate cells. Hepatol Res 26, 232236.
  • 57
    Castellino RC & Durden DL (2007) Mechanisms of disease: the PI3K–Akt–PTEN signaling node – an intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol 3, 682693.
  • 58
    Deeken JF & Loscher W (2007) The blood–brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 13, 16631674.
  • 59
    Lee SW, Kim WJ, Choi YK, Song HS, Son MJ, Gelman IH, Kim YJ & Kim KW (2003) SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier. Nat Med 9, 900906.
  • 60
    Fukumura D, Xu L, Chen Y, Gohongi T, Seed B & Jain RK (2001) Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 61, 60206024.
  • 61
    Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP & Jain RK (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 95, 46074612.
  • 62
    Monsky WL, Fukumura D, Gohongi T, Ancukiewcz M, Weich HA, Torchilin VP, Yuan F & Jain RK (1999) Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res 59, 41294135.
  • 63
    Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF & Jain RK (1994) Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 54, 45644568.
  • 64
    Monsky WL, Mouta Carreira C, Tsuzuki Y, Gohongi T, Fukumura D & Jain RK (2002) Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin Cancer Res 8, 10081013.
  • 65
    Fidler IJ, Yano S, Zhang RD, Fujimaki T & Bucana CD (2002) The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 3, 5357.
  • 66
    Bullitt E, Zeng D, Gerig G, Aylward S, Joshi S, Smith JK, Lin W & Ewend MG (2005) Vessel tortuosity and brain tumor malignancy: a blinded study. Acad Radiol 12, 12321240.
  • 67
    Plate KH & Mennel HD (1995) Vascular morphology and angiogenesis in glial tumors. Exp Toxicol Pathol 47, 8994.
  • 68
    Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E et al. (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553563.
  • 69
    Zagzag D, Hooper A, Friedlander DR, Chan W, Holash J, Wiegand SJ, Yancopoulos GD & Grumet M (1999) In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 159, 391400.
  • 70
    Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG & Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8, 610622.
  • 71
    Jain RK, Tong RT & Munn LL (2007) Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 67, 27292735.
  • 72
    Grizzi F, Russo C, Colombo P, Franceschini B, Frezza EE, Cobos E & Chiriva-Internati M (2005) Quantitative evaluation and modeling of two-dimensional neovascular network complexity: the surface fractal dimension. BMC Cancer 5, 14.
  • 73
    Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A & Isner JM (1998) Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 97, 99107.
  • 74
    Sirois MG & Edelman ER (1997) VEGF effect on vascular permeability is mediated by synthesis of platelet-activating factor. Am J Physiol 272, H2746H2756.
  • 75
    Wu HM, Huang Q, Yuan Y & Granger HJ (1996) VEGF induces NO-dependent hyperpermeability in coronary venules. Am J Physiol 271, H2735H2739.
  • 76
    Dvorak AM & Feng D (2001) The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. J Histochem Cytochem 49, 419432.
  • 77
    Hippenstiel S, Krull M, Ikemann A, Risau W, Clauss M & Suttorp N (1998) VEGF induces hyperpermeability by a direct action on endothelial cells. Am J Physiol 274, L678L684.
  • 78
    Mayhan WG (1999) VEGF increases permeability of the blood–brain barrier via a nitric oxide synthase/cGMP-dependent pathway. Am J Physiol 276, C1148C1153.
  • 79
    Helmlinger G, Yuan F, Dellian M & Jain RK (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3, 177182.
  • 80
    Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20, 43684380.
  • 81
    Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocrin Rev 25, 581611.
  • 82
    Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M et al. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 8395.
  • 83
    Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6, 273286.
  • 84
    Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM et al. (2007) Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25, 16511657.
  • 85
    Paris D, Quadros A, Patel N, DelleDonne A, Humphrey J & Mullan M (2005) Inhibition of angiogenesis and tumor growth by beta and gamma-secretase inhibitors. Eur J Pharmacol 514, 115.
  • 86
    Newton HB (2004) Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev Anticancer Ther 4, 105128.
  • 87
    Iwamaru A, Kondo Y, Iwado E, Aoki H, Fujiwara K, Yokoyama T, Mills GB & Kondo S (2007) Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene 26, 18401851.
  • 88
    Conrad C FH, Reardon D, Conrad C, Friedman H, Reardon D, Provenzale J, Jackson E, Serajuddin H, Laurent D, Chen B et al. (2004) A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM) [abstract]. J Clin Oncol 22, 1512.
  • 89
    Reardon D, Friedman H, Yung WKA, Brada M, Conrad C, Provenzale J, Jackson E, Serajuddin HCB & Laurent D (2004) A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM) [abstract]. J Clin Oncol 22, 1513.
  • 90
    Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7, 987989.
  • 91
    Baluk P, Hashizume H & McDonald DM (2005) Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15, 102111.
  • 92
    Jain RK (2005) Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19, 716.
  • 93
    Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 5862.
  • 94
    Jain RK, Duda DG, Clark JW & Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3, 2440.
  • 95
    Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, Benjamin L, Yuan F & Keshet E (1998) Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA 95, 1082010825.
  • 96
    Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ & Jain RK (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64, 37313736.
  • 97
    Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N & Jain RK (1996) Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93, 1476514770.
  • 98
    Izumi Y, Xu L, di Tomaso E, Fukumura D & Jain RK (2002) Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416, 279280.
  • 99
    Weichselbaum RR (2005) How does antiangiogenic therapy affect brain tumor response to radiation? Nat Clin Pract Oncol 2, 232233.
  • 100
    Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV et al. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10, 145147.
  • 101
    Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ & Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407, 242248.
  • 102
    Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW et al. (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59, 33743378.
  • 103
    Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z & Kolesnick R (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 11551159.
  • 104
    Moeller BJ, Cao Y, Li CY & Dewhirst MW (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5, 429441.
  • 105
    Jiang F, Zhang ZG, Katakowski M, Robin AM, Faber M, Zhang F & Chopp M (2004) Angiogenesis induced by photodynamic therapy in normal rat brains. Photochem Photobiol 79, 494498.
  • 106
    Kim JH, Chung YG, Kim CY, Kim HK & Lee HK (2004) Upregulation of VEGF and FGF2 in normal rat brain after experimental intraoperative radiation therapy. J Korean Med Sci 19, 879886.
  • 107
    Tsao MN, Li YQ, Lu G, Xu Y & Wong CS (1999) Upregulation of vascular endothelial growth factor is associated with radiation-induced blood–spinal cord barrier breakdown. J Neuropathol Exp Neurol 58, 10511060.
  • 108
    Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD & Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432, 396401.
  • 109
    Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M et al. (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11, 6982.
  • 110
    Wong ET & Brem S (2008) Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. J Natl Compr Cancer Network 6, 515522.
  • 111
    Bergers G & Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8, 592603.
  • 112
    Pope WB, Lai A, Nghiemphu P, Mischel P & Cloughesy TF (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66, 12581260.
  • 113
    Li Q, Ford MC, Lavik EB & Madri JA (2006) Modeling the neurovascular niche: VEGF- and BDNF-mediated cross-talk between neural stem cells and endothelial cells: an in vitro study. J Neurosci Res 84, 16561668.
  • 114
    Ferrara N, Gerber HP & LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9, 669676.
  • 115
    Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E et al. (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99, 1139311398.